Cardiol Therapeutics Inc. Forecasted to Earn Q2 2024 Earnings of ($0.09) Per Share (NASDAQ:CRDL)

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Roth Capital issued their Q2 2024 EPS estimates for Cardiol Therapeutics in a note issued to investors on Wednesday, June 26th. Roth Capital analyst J. Wittes anticipates that the company will post earnings of ($0.09) per share for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.34) per share. Roth Capital also issued estimates for Cardiol Therapeutics’ Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.39) EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.04).

CRDL has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a report on Friday, June 14th. Roth Mkm initiated coverage on shares of Cardiol Therapeutics in a report on Wednesday. They set a “buy” rating and a $10.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on shares of Cardiol Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, May 23rd. Finally, Canaccord Genuity Group boosted their price objective on shares of Cardiol Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, May 23rd. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Cardiol Therapeutics has a consensus rating of “Buy” and a consensus target price of $7.60.

Cardiol Therapeutics Price Performance

Shares of CRDL opened at $2.02 on Friday. The firm has a market capitalization of $139.38 million, a PE ratio of -5.77 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.81 and a quick ratio of 2.81. Cardiol Therapeutics has a 1-year low of $0.66 and a 1-year high of $3.12. The company’s fifty day moving average price is $2.21 and its 200-day moving average price is $1.65.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cardiol Therapeutics stock. Tejara Capital Ltd grew its position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 29.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 645,457 shares of the company’s stock after acquiring an additional 148,396 shares during the period. Tejara Capital Ltd owned about 1.00% of Cardiol Therapeutics worth $578,000 at the end of the most recent quarter. 12.49% of the stock is currently owned by hedge funds and other institutional investors.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.